Dual checkpoint blockade is also being explored: nivolumab, a PD-1 inhibitor, and ipilimumab, a CTLA-4 inhibitor, act synergistically by enhancing T-cell activation and reducing tumor-induced immunosuppression [127]. Here, PDCD1 is linked to neoplasm.